CJC-1295 DAC is a long-acting GHRH analog: the Drug Affinity Complex modification binds it to serum albumin, giving it a half-life of roughly 8 days, so a single subcutaneous injection sustains growth-hormone stimulation for over a week (Teichman et al., 2006, PMID: 16352683). That sustained-release profile is what shapes the entire results timeline. Where short-acting GHRH peptides produce brief, repeated GH pulses, the DAC version raises IGF-1 toward a steady state and holds it there — which means the biochemistry moves fast while the visible changes lag well behind it.
Research-context information only. CJC-1295 DAC is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This timeline maps what the clinical data documents against what community sources self-report at each stage. Individual response varies with age, baseline GH status, training, sleep, and dosing consistency. Community doses cluster around 2 mg once or twice weekly; protocol detail lives in the CJC-1295 DAC dosing guide. For how the long-acting DAC version differs from the short-acting no-DAC form across the full timeline, see the combined CJC-1295 results timeline.
The first week is almost entirely biochemical. The albumin-bound peptide is establishing sustained GHRH-receptor stimulation, and the measurable shifts happen on bloodwork, not in the mirror.
What the clinical data shows:
A single CJC-1295 DAC injection raised IGF-1 by 1.5-3 fold within roughly 2-4 days, with levels staying elevated for 9-11 days; mean plasma GH rose 2-10 fold for 6 or more days (Teichman et al., 2006, PMID: 16352683).
Pulsatile GH secretion was preserved despite the continuous stimulation — the natural overnight GH burst still fires, just from a higher trough (Ionescu & Bhatt, 2006, PMID: 17018654).
The documented link between GHRH stimulation and slow-wave sleep sets up the earliest subjective signal: roughly 70% of nightly GH secretion coincides with slow-wave sleep in men (Van Cauter & Plat, 1996, PMID: 8627466).
What community sources commonly describe:
Deeper sleep and more vivid dreams toward the end of week 1
A mild sense of well-being some users attribute to better sleep
In many reports, nothing noticeable at all in the first seven days
What the data does not support yet: visible fat loss, muscle changes, or measurable body-composition shifts. Community reports of "feeling nothing" in week 1 are common and consistent with the gradual, sustained pharmacology the trial data describes.
Weeks 2-4: Sleep and Recovery Reports Stabilize
Across the first 2-3 injections the peptide reaches steady-state IGF-1 elevation, because each dose overlaps the long tail of the previous one. After multiple weekly doses in the pivotal trial, IGF-1 remained above baseline for up to 28 days (Teichman et al., 2006, PMID: 16352683).
What community sources commonly describe in this window:
Deeper, more reliable sleep — reported as the most consistent early effect rather than an occasional one
Faster recovery between training sessions and less day-after soreness
Subtle reductions in subcutaneous water and minor skin-quality changes
Appetite shifts in either direction — some users in community sources report more hunger, others report steadier appetite
These are self-reported subjective milestones; no trial measured sleep or recovery as a CJC-1295 DAC endpoint, so they sit at the community-evidence tier while the IGF-1 elevation behind them sits at the clinical-data tier. The mechanistic bridge between the two is the documented slow-wave-sleep / GH relationship (Van Cauter & Plat, 1996, PMID: 8627466).
This is the stage where sustained IGF-1 elevation starts translating into changes users can see and measure. Trial subjects and community sources commonly describe a 6-8 week lag before body-composition effects become noticeable, which fits the slow, cumulative profile of a long-acting GHRH analog rather than an acute fat-loss agent.
What the clinical data shows for the GHRH-analog class:
Sixteen weeks of nightly GHRH-(1-29) administration in age-advanced men and women produced favorable body-composition shifts alongside the expected GH/IGF-1 elevation (Vittone et al., 1997, PMID: 9141536). This is class-level GHRH-analog evidence, not a CJC-1295 DAC body-composition trial.
Serum-protein changes consistent with an activated GH/IGF-1 axis were documented one week after a CJC-1295 dose, with one protein marker tracking linearly with IGF-1 levels (Jette et al., 2009, PMID: 19386527).
What community sources commonly describe:
Gradual reduction in midsection and visceral-area fat
Improved muscle fullness and recovery rather than rapid size gains
Continued skin-quality reports — hydration and elasticity attributed to GH-driven collagen turnover
Community reports consistently frame these as gradual and training-dependent, not standalone effects. The recurring community caveat is that CJC-1295 DAC is described as amplifying an existing training and nutrition stimulus, not replacing one.
Months 3-6: Stabilization and Plateau
Beyond two months, community reports describe the early changes consolidating rather than accelerating. The trial data does not extend to this window for CJC-1295 DAC specifically — the longest dosing data is the 28-day IGF-1 persistence after multiple doses (Teichman et al., 2006, PMID: 16352683) and the 16-week GHRH-analog class data (Vittone et al., 1997, PMID: 9141536) — so this stage rests more on community timelines than on direct clinical evidence.
What community sources commonly describe:
Fat loss continuing at a slower rate after the initial weeks, described as refinement rather than dramatic change
Recovery capacity that felt enhanced earlier settling into a new normal baseline
Sustained sleep and skin-quality reports for users who stay consistent
On cycling: community protocols commonly run 12-16 weeks on with a break, typically for cost and to let IGF-1 normalize rather than because a desensitization threshold has been established. No long human trials have evaluated continuous CJC-1295 DAC use, so the on/off convention is a community practice, not a trial-validated requirement. For background on the desensitization question, see Do GH Peptides Desensitize the Pituitary?. Community sources describe IGF-1 returning toward baseline over roughly 2-4 weeks once dosing stops.
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
The timeline above describes a middle-of-the-road response. Several variables determine whether an individual lands on the faster or slower end.
Dosing consistency. Because the DAC version reaches steady state across the first 2-3 injections, community sources describe missed or irregular injection days as the most common reason IGF-1 never accumulates to a stable level. Fixed weekly days are the most frequently described approach.
Injection timing relative to food. GH release is blunted by elevated blood glucose and insulin. Community sources describe spacing injections away from large carbohydrate meals; the long half-life makes exact timing less critical here than it is for the short-acting no-DAC version.
Age and baseline GH status. GH secretion declines roughly 2-3 fold between ages 30 and 40 in published physiology, so older users with a larger deficit are the group community sources most often describe noticing pronounced effects. Younger users with healthy baselines commonly report subtler changes.
Sleep, training, and nutrition. The body-composition evidence is class-level and training-paired — the GHRH-(1-29) trial subjects who showed composition shifts were monitored over 16 weeks of consistent dosing (Vittone et al., 1997, PMID: 9141536). Community reports consistently describe weak results when sleep is poor or training is absent.
Product quality. Community sources repeatedly tie flat responses to unverified product. A third-party COA is the most commonly cited check.
When the Data Says to Reassess
This section reports the signals community sources and trial data describe — not instructions.
Signals commonly read as a response:
Deeper sleep reported in the first 1-2 weeks (community)
IGF-1 movement from baseline on bloodwork at 4-6 weeks (the clinical marker — Teichman et al., 2006, PMID: 16352683)
Recovery and body-composition reports emerging at 4-8 weeks (community)
Signals community sources describe as reasons to re-evaluate:
No subjective change and no IGF-1 movement by 4-6 weeks despite consistent dosing — community sources point to product verification, injection timing, and dosing consistency
Water retention, bloating, or hand numbness/tingling — community sources describe these as classic GH-excess fluid-retention signs and a cue that the dose may be high; trial-reported adverse events were mild and no serious events occurred (Teichman et al., 2006, PMID: 16352683)
No body-composition change by month 3 despite IGF-1 elevation — community sources attribute this to diet and training rather than the peptide, consistent with the class evidence being training-paired
Clinical data shows IGF-1 begins rising within 2-4 days of the first injection and stays elevated for 9-11 days (Teichman et al., 2006). Community sources commonly describe deeper sleep within the first 1-2 weeks, with body-composition changes reported gradually over 4-8 weeks of consistent use.
What is the first sign CJC-1295 DAC is doing something?
The most consistent early community report is improved sleep depth and more vivid dreams, usually described within the first 1-2 weeks. This aligns with the documented relationship between GHRH stimulation and slow-wave sleep (Van Cauter & Plat, 1996). The biochemical first sign — IGF-1 elevation — is only visible on bloodwork.
Why does the long half-life change the timeline?
CJC-1295 DAC binds serum albumin, giving it a roughly 8-day half-life (Teichman et al., 2006). A single dose sustains GHRH-receptor stimulation for over a week, so IGF-1 accumulates toward steady state across the first 2-3 injections rather than spiking and clearing each day. The trade-off the data describes is a more sustained, lower-amplitude GH profile.
What did trials report about IGF-1 levels on CJC-1295 DAC?
Teichman et al. (2006) reported single-dose IGF-1 increases of 1.5-3 fold lasting 9-11 days in healthy adults, and after multiple weekly doses IGF-1 remained above baseline for up to 28 days. Half-life was estimated at 5.8-8.1 days. No serious adverse events were reported in that trial.
What do community sources describe when nothing seems to be happening?
Community reports of a flat response commonly point to inconsistent injection days, blood-sugar elevation around injection time (insulin blunts GH release), short timeframes, or unverified product without a third-party COA. Bloodwork showing IGF-1 movement from baseline is how community sources separate a biochemical response from an outlier.
Research Supplies for CJC-1295 with DAC
Hand-picked storage, injection, and recovery supplies paired with CJC-1295 with DAC protocols.
Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
Ionescu M, Bhatt DL, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654
Vittone J, Blackman MR, Busby-Whitehead J, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141536
Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996;128(5 Pt 2):S32-S37. PMID: 8627466
Jette L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527
For educational and research purposes only. This is not medical advice. CJC-1295 DAC is a research peptide with published clinical data for GH/IGF-1 stimulation but no FDA approval for body-composition or anti-aging use.
